Over 500 sufferers with metastatic bone and soft-tissue sarcomas have already been signed up for the trial to day. Full patient enrollment is likely to happen by year-end 2009, and the second interim analysis based on around two-thirds of the full total quantity of progression-free survival events is anticipated by the end of the first one fourth of 2010, as announced previously. Berger, M.D., chairman and ceo of ARIAD.. ARIAD to complete it is Phase 3 SUCCEED trial following DMS recommendation ARIAD Pharmaceuticals, Inc. today announced that the independent Data Monitoring Committee of the Phase 3 SUCCEED trial provides completed the first interim efficacy analysis as specified by the analysis protocol and has suggested that the randomized, placebo-controlled trial of oral ridaforolimus in individuals with metastatic sarcomas continue to full affected person completion and enrollment.This developing collaboration between AHF and our esteemed Cambodian companions includes the delivery of innovative medical and nonmedical interventions; providing technical support and training assets to increase and strengthen the diagnostic and treatment capability and skills of HIV/AIDS and ART treatment providers providers in Cambodia – – all of which will now also take place in Kandal Province, said Henry E. Chang, AHF’s Chief of Global Affairs. AHF has significant experience and experience in ART service delivery and abilities and capacity building related to HIV/Helps treatment and care, and we are consequently well-positioned to complement the Cambodian Ministry of Wellness in its initiatives to improve access to prevention, treatment and treatment at these facilities in Cambodia.